Search clinical trials for: osimertinib

Total 285 results

Second Affiliated Hospital of Nanchang University
Nanchang University

Unknown

Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis (OWONBNSCLCLM)

Non-small Cell Lung Cancer | EGFR Activating Mutation | Leptomeningeal Metastasis
Fudan University

Unknown

Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC (PCA)

NSCLC Stage IV

China
University of California, San Diego
Abbott

Completed

Naturalistic Study, Comparison of Divalproex Extended Release (ER) and Quetiapine for Adults With Acute Mania or Mixed Episodes

Bipolar Disorder

United States
Tianjin Medical University Cancer Institute and...
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of Anlotinib Combined With Osimertinib as Second-line Treatment in Stage IIIb-IV NSCLC With Confirmed EGFRm and T790M (ALTN-03)

Non Small Cell Lung Cancer

China
AstraZeneca
Quintiles, Inc.

Completed

Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)

United States
Tufts University

Completed

Bioavailability of Ubiquinone and Ubiquinol in Older Adults

Absorption

United States
AstraZeneca

Completed

Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment

Solid Tumours

United States, Spain, Belgium, France, Korea, Republic of, United Kingdom
Hellenic Oncology Research Group

Unknown

Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLC

Non Small Cell Lung Cancer

Greece
Cumberland Pharmaceuticals

Completed

Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI) (FAST2)

Infections, Gram-positive Bacterial

United States
AstraZeneca

Completed

Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC

T790M Positive NSCLC Patients

China
Peking Union Medical College Hospital

Unknown

Serological Response to Retreatment of Serofast Early Syphilis Cases With Benzathine Penicillin

Syphilis

China
National University Hospital, Singapore
AstraZeneca; Singapore Clinical Research Institute

Unknown

Phase II Study of AZD9291 in Advanced Stage NSCLC With EGFR and T790M Mutations Detected in Plasma Ct-DNA (PLASMA)

Carcinoma, Non-Small-Cell Lung

Taiwan, Hong Kong, Thailand, Singapore, Korea, Republic of
Gustave Roussy, Cancer Campus, Grand Paris

Completed

Trial Comparing Trabectedin to the Best Supportive Care in Patients With Sarcoma (TSAR)

Soft Tissue Sarcoma

France
AstraZeneca

Completed

Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

Spain, United Kingdom, France, United States
Sun Yat-sen University

Unknown

Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer

Non-small Cell Lung Cancer

China
Qingdao Central Hospital

Completed

Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer

Progression Free Survival

China
AstraZeneca

Terminated

Observational Study of Patients With Locally Advanced or Metastatic NSCLC (Non-Small Cell Lung Cancer) (PANORAMA)

Carcinoma, Non-Small-Cell Lung

France, Spain, United Kingdom, China, Canada, Taiwan
Samsung Medical Center

Unknown

Uncommon EGFR AZD9291

Non Small Cell Lung Cancer

Korea, Republic of
AstraZeneca

Completed

To Determine the Relative Bioavailability of Different Formulations of AZD9291 and the Effect of Food.

Healthy Volunteers

United States
Peking University Third Hospital

Unknown

Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

Nonsmall Cell Lung Cancer

China
Guangdong Association of Clinical Trials

Unknown

PD-L1 and Other Immuno-markers Influenced by Osimertinib Treatment in Advanced NSCLC Patients (ATHENE)

Small Cell Lung Cancer, Polygonal Type

China
Catherine Buettner
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Completed

Clinical Trial of CoQ10 for Mild-to-Moderate Statin-Associated Muscle Symptoms

Pain | Weakness | HMG COA Reductase Inhibitor Adverse Reaction | Cramps | Myalgia or Myositis Nos

United States
Shandong Cancer Hospital and Institute
AstraZeneca

Unknown

Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M

Nonsmall Cell Lung Cancer | Brain Metastases | EGFR-TKI Resistant Mutation | AZD9291
AstraZeneca

Completed

A Phase I, Open-label Study to Assess Bioavailability of a Single Oral Dose of AZD9291 vs an IV Dose of [14C]AZD9291

Oncology

United Kingdom
AstraZeneca

No longer available

AZD9291 US Expanded Access Program

EGFR T790M Mutation Positive NSCLC

United States
AstraZeneca

Completed

Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers

Healthy Volunteer

United States
AstraZeneca

Completed

Study Evaluating the Pharmacokinetic and Mass Balance of Single Dose [14C] AZD9291 in Volunteers

Healthy Volunteers

United Kingdom
University of California, San Diego
National Institute on Aging (NIA)

Completed

UCSD Q10 and Aging Study

Age Related Symptoms | Age Related Quality of Life Issues

United States
Mansoura University

Completed

Coenzyme Q10 and Clomiphene Citrate (CC) for Ovulation Induction in Polycystic Ovary Syndrome

Polycystic Ovary Syndrome

Egypt
National University Hospital, Singapore

Completed

Effects of High-dose Coenzyme Q10 on Biomarkers of Oxidative Damage and Clinical Outcome in Parkinson Disease

Parkinson Disease

Singapore
European Organisation for Research and Treatment...

Completed

Ecteinascidin 743 in Treating Adults With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

France, Spain, Denmark, Netherlands, Norway, Belgium, United Kingdom, Israel, Italy, Switzerland, Germany, Austria, Greece, Portugal
Colombian Neonatal Research Network
Abbott; Fisher and Paykel Healthcare; Vanderbilt University School of Medicine; Pontificia Universidad Javeriana

Completed

Very Early Surfactant and NCPAP for Premature Infants With RDS (CNRNCPAP)

Respiratory Distress Syndrome | Chronic Lung Disease | Pneumothorax/Pulmonary Intersticial Emphysema

Colombia
Agency for Healthcare Research and Quality (AHRQ)
Marshfield Clinic Research Foundation

Unknown

Modeling Genotype and Other Factors to Enhance the Safety of Coumadin Prescribing

Atrial Fibrillation | Pulmonary Embolism | Deep Venous Thrombosis | Heart Valve Replacement

United States
The Hospital for Sick Children

Unknown

Surfactant Lavage vs. Bolus Surfactant in Neonates With Meconium Aspiration

Meconium Aspiration Syndrome

Canada
Luzerner Kantonsspital

Completed

Study to Investigate Effects of Antiischemic Drug Therapy in Silent Ischemia

Myocardial Ischemia

Switzerland

Search clinical trials for: osimertinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations